iatroX logo
brainstormaskiatroXquizcpdknowledge centrehow it worksaboutblog
Knowledge Centre / Corticosteroid-Induced Osteoporosis

Corticosteroid-Induced Osteoporosis

Prevention and management of bone loss due to steroids.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 22 August 2025
EndocrinologyRheumatology

Clinical Guidelines

CKS: Osteoporosis - Prevention of Fragility Fractures
National
SIGN 142: Management of osteoporosis and the prevention of fragility fractures
National

Recent iatroX Q&As

  • What are the recommended strategies for preventing corticosteroid-induced osteoporosis in patients starting long-term steroid therapy?Updated: 8/22/2025
  • How often should I monitor bone mineral density in patients on chronic corticosteroid treatment?Updated: 8/22/2025
  • What pharmacological options are available for the management of corticosteroid-induced osteoporosis, and when should they be initiated?Updated: 8/22/2025
  • Which patients on corticosteroids should be referred for specialist assessment regarding osteoporosis management?Updated: 8/22/2025
  • What lifestyle modifications should I advise to patients at risk of corticosteroid-induced osteoporosis?Updated: 8/22/2025
ask iatroX
privacy terms faq
UKCA Mark

iatroX is a UKCA-marked, MHRA-registered medical device.

Download on the App StoreGet it on Google Play